A Phase II, Randomised, Open Label Pilot Study to Evaluate the Efficacy and Safety of Two Dosage Regimens of Subcutaneous Bioresorbable Afamelanotide Implants in Patients With Mild to Moderate Acne Vulgaris
Latest Information Update: 28 Oct 2021
At a glance
- Drugs Afamelanotide (Primary)
- Indications Acne vulgaris
- Focus Therapeutic Use
- Sponsors Clinuvel Pharmaceuticals
Most Recent Events
- 07 Jul 2021 New trial record